NYSE · CVS

CVS HEALTH Corporation

$107.74 +$0.85 (+0.80%) 1D After hours
Charting by TradingView

Key Metrics

$136.38B
Market cap
46.52×
P/E · TTM
$407.91B
Revenue · TTM
$2.93B
Net income
EPS · TTM $2.32
Dividend yield 2.5%
Free cash flow $7.39B
Beta · 1Y 0.12
EBITDA · TTM $8.02B
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    Money has been moving out of its sector (Consumer Discretionary).

    Consumer Discretionary has run -5.7 points vs SPY over four weeks, ranking 3→5→10→11 of 11 sectors — this stock trades inside that current.

    RECEIPT: ROTATION MAP, LIVE ↗
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$136.38B
Enterprise value$155.29B
Shares outstanding1.3B
52-wk range$58.99 – $110.68
Avg volume · 20D8.3M
Net cash −$18.90B
Book value / share$61.28
IndustryRetail-Drug Stores And Proprietary Stores
ExchangeNYSE
About CVS HEALTH Corporation
IPO dateOct 1, 1952
Employees300000

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E46.52
P/S0.33
P/FCF18.45
EV/EBITDA19.35
EV/Sales0.38
Graham №$56.55

Profitability

Gross —
Operating 0.8%
Net 0.7%
FCF 1.8%
ROE / ROIC 3.8% · 2.3%

Financial Health

Current ratio0.87
Quick ratio0.66
Debt / equity0.81
Debt / EBITDA 7.87
Net cash −$18.90B
Working capital−$11.59B

Cash Flow · TTM

Operating CF $10.33B
Capex −$2.94B
Free cash flow $7.39B
Buybacks —
Dividends paid $3.40B
Shareholder yield 2.5%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

2.4
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$56.55 vs $107.74
Trades 1.9× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings